Arcturus Therapeutics (ARCT) said Monday it started dosing patients with cystic fibrosis and ornithine transcarbamylase deficiency in phase 2 multiple ascending dose studies in December 2024.
Patients in the phase 2 cystic fibrosis study are expected to get daily treatments of ARCT-032 over a 28-day period, according to the company.
Patients with ornithine transcarbamylase deficiency will receive five intravenous infusions of ARCT-810 over two months and the first participant in the US received 0.5 milligrams per kilogram dose in December.
The company expects phase 2 interim data for both program in H1.
Arcturus shares were up more than 6% in regular trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。